Teva Pharmaceutical Industries Ltd (ADR)  

(Public, NYSE:TEVA)   Watch this stock  
Find more results for TEVA
+0.32 (1.77%)
Mar 16 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 17.90 - 18.92
52 week 10.85 - 34.09
Open 18.00
Vol / Avg. 16.84M/15.77M
Mkt cap 18.53B
P/E     -
Div/yield 0.09/4.63
EPS -17.30
Shares 1.02B
Beta 0.65
Inst. own 60%
May 9, 2018
Q1 2018 Teva Pharmaceutical Industries Ltd Earnings Release (Estimated) - 7:00AM EDT - Add to calendar
Mar 13, 2018
Teva Pharmaceutical Industries Ltd at Cowen Health care Conference
Feb 8, 2018
Q4 2017 Teva Pharmaceutical Industries Ltd Earnings Call - Webcast
Feb 8, 2018
Q4 2017 Teva Pharmaceutical Industries Ltd Earnings Release
Jan 8, 2018
Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin -234.44% -78.21%
Operating margin -238.41% -78.29%
EBITD margin - 26.75%
Return on average assets -65.52% -21.39%
Return on average equity -261.91% -80.96%
Employees 51,800 -
CDP Score - A-


5 Basel St., P.O. Box 3190
+972-3-9267267 (Phone)
+972-3-9234050 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.

Officers and directors

Sol J. Barer Ph.D. Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Kaare Schultz President, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Michael McClellan Chief Financial Officer, Executive Vice President
Bio & Compensation  - Reuters
Iris Beck-Codner Executive Vice President - Global Brand & Communications
Age: 52
Bio & Compensation  - Reuters
Richard Daniell Executive Vice President - European Commercial
Bio & Compensation  - Reuters
Carlo de Notaristefani Executive Vice President - Global Operations
Age: 59
Bio & Compensation  - Reuters
Sven Dethlefs Ph.D. Executive Vice President - Global Marketing & Portfolio
Bio & Compensation  - Reuters
Hafrun Fridriksdottir Executive Vice President - Global R&D
Age: 55
Bio & Compensation  - Reuters
Gianfranco Nazzi Executive Vice President - Growth Markets Commercial
Bio & Compensation  - Reuters
Brendan O'Grady Executive Vice President - North America Commercial
Bio & Compensation  - Reuters